Eli Lilly projects higher first-quarter profit and revenue on weight-loss drug demand
Updated
Updated · MarketWatch · Apr 29
Eli Lilly projects higher first-quarter profit and revenue on weight-loss drug demand
10 articles · Updated · MarketWatch · Apr 29
Analysts expect Eli Lilly to report a $6.61 billion profit and $17.82 billion revenue, both sharply higher than last year’s results.
The company’s growth is fueled by strong sales of weight-loss drugs, though its new Foundayo pill has shown softer prescription volumes compared to Novo Nordisk’s Wegovy.
Eli Lilly has recently made several major acquisitions, including Ajax Therapeutics, as investors await commentary on its M&A strategy and the impact of U.S. pricing pressures on Zepbound.
As Eli Lilly's profits are set to break records, why has its stock fallen 17%?
Beyond weight loss, what does Lilly's pipeline reveal about the next medical breakthrough?
How will the market change with Lilly's new oral pill challenging injectable drugs?
With regulators cracking down, what is the future for users of 'knock-off' diet drugs?
Can the average person truly afford the new generation of weight-loss pills?
Are we entering an era of lifelong medical dependency to manage weight?